Patients stayed stable after switching to Bristol Myers' Cobenfy About 86% completed 8 weeks, and no patients stopped Cobenfy for lack of efficacy, giving clinicians data on faster and slower switch strategies.

#BMY Open Label Outpatient Switch Study Demonstrates Symptom Stability During Transition from Oral Atypical Antipsychotics to Cobenfy™ (xanomeline and trospium chloride)

www.stocktitan.net/news/BMY/open-label-outp...

Three New Studies Show Viz.ai’s Cardio Suite Speeds Detection of Cardiac Disease and Improves Patient Follow-Up Viz.ai will present three abstracts on Viz HCM, its AI-ECG solution within the Viz Cardio Suite, at ACC.26 (March 28–30, 2026).Key findings include 11 new real-world HCM diagnoses, 13% progression from AI-positive/phenotype-negative over 2.74 years, and that Viz HCM is the first FDA-cleared AI algorithm for HCM detection from a standard 12-lead ECG. The tool was developed under a multi-year agreement with Bristol Myers Squibb (NYSE: BMY).

#BMY Three New Studies Show Viz.ai’s Cardio Suite Speeds Detection of Cardiac Disease and Improves Patient Follow-Up

www.stocktitan.net/news/BMY/three-new-studi...

AI drug discovery deal widens as Bristol Myers adds 2 ALS targets insitro gets a $10M milestone as the partners push oligonucleotide and small-molecule ALS programs aimed at underlying disease drivers.

#BMY insitro and Bristol Myers Squibb Collaboration Expanded with Nomination of New Targets

www.stocktitan.net/news/BMY/insitro-and-bri...

Bristol Myers Squibb Announces Positive Phase 3 Results from the SUCCESSOR-2 Study of Oral Mezigdomide in Relapsed or Refractory Multiple Myeloma Bristol Myers Squibb (NYSE: BMY) announced positive interim Phase 3 results from the SUCCESSOR-2 study of oral mezigdomide combined with carfilzomib and dexamethasone (MeziKd) in relapsed or refractory multiple myeloma. MeziKd showed a statistically significant, clinically meaningful improvement in progression-free survival (PFS) versus carfilzomib and dexamethasone alone.Safety was consistent with the known profile; patients will continue to be followed for overall survival and long-term safety. Data will be presented at a future medical meeting and shared with health authorities.

#BMY Bristol Myers Squibb Announces Positive Phase 3 Results from the SUCCESSOR-2 Study of Oral Mezigdomide in Relapsed or Refractory Multiple Myeloma

www.stocktitan.net/news/BMY/bristol-myers-s...

Bloomsbury boosted by Maas books news Discover how Bloomsbury boosted by Maas books news and saw a share price rally. Get the latest on upcoming novels.

Bloomsbury boosted by Maas books news:

FY27 profit expected to be ‘materially ahead’ of consensus

#BMY $BMY

sharesify.com/bloomsbury-b...

Bloomsbury boosted by Maas books news Explore how Bloomsbury boosted by Maas books news, projecting significant growth in FY27 profits with new releases.

Bloomsbury boosted by Maas book news:

FY27 profit expected to be ‘materially ahead’ of consensus

#BMY $BMY

sharesify.com/bloomsbury-b...

UK companies in the news:

#3IN #ABF #ADM #AUSC #AV #BMY #CABP #CGEO #CRDL #DRX #EDV #ELM #ENT #FCH #FOXT #FSFL #GFTU #GRP #HBR #HE1 #HSP #HTG #IBST #IGG #ITV #LRE #OSB #PAGE #RKT #RM #RTO #SERE #SMWH #SNR #SPI #SRP #SSIT #TFW #TW #VTU

Head to Sharesify.com for news, views and analysis.

#BMY TU. FY25/26 expected inline, FY26/27 now expected to be materially ahead after yesterday evenings Sarah J Maas update to release two new books within 11 weeks of each other.

The Logical Investor Newsletter: February 2026 (Selling VZ & BMY + A New Buy) This month, we’re SELLING ALL of Two positions (VZ and BMY) and buying a new pick! So, let’s get into the nitty gritty as to why we’re doing this now. For VZ, we’re up 23% in a mere THREE months.

The latest monthly newsletter is out with us taking profits on two positions and a new buy: logicalinvestor.net/members-only... #VZ #BMY #stocks #stockmarket #investing

Bought #BMY - at 52 week low - AI mentioned and hopefully bounce from this level

Microsoft has partnered with Bristol Myers to implement FDA-cleared radiology AI algorithms through Microsoft’s Precision Imaging Network.

#MSFT #BMY #Microsoft #AI #MedTech

Bristol Myers Squibb Announces Collaboration with Microsoft to Advance AI-Driven Early Detection of Lung Cancer Bristol Myers Squibb (NYSE: BMS) announced a collaboration with Microsoft on January 20, 2026 to deploy U.S. FDA-cleared radiology AI algorithms for lung cancer detection via Microsoft’s Precision Imaging Network. The initiative aims to automatically analyze X-ray and CT images to surface hard-to-detect lung nodules, accelerate identification of potential Non‑Small Cell Lung Cancer (NSCLC) cases, and route patients into care pathways.The program emphasizes expanding early detection and follow-up in medically underserved communities, leveraging workflow tools to address that >50% of patients with incidental findings are lost to follow-up and noting Microsoft’s network reaches more than 80% of U.S. hospitals.

#BMS #BMY Bristol Myers Squibb Announces Collaboration with Microsoft to Advance AI-Driven Early Detection of Lung Cancer

www.stocktitan.net/news/BMS/bristol-myers-s...

📈 Heavy institution #Equity #optionsvolume! Weekly Top Equity Activity from 🔥 INSIDERFINANCE.COM

📈 Heavy institution #Equity #optionsvolume!

Weekly Top Equity Activity from 🔥 INSIDERFINANCE.COM 🔥
1. #NVDA 1.0M
2. #TSLA 544.6K
3. #INTC 195.4K
4. #AGNC 156.3K
5. #BMY 146.2K

#OptionFlow #OptionsTrading #Trading

🚨 Institutions #optionsvolume surge detected! PM Top Momentum Activity from 🔥 INSIDERFINANCE.COM

🚨 Institutions #optionsvolume surge detected!

PM Top Momentum Activity from 🔥 INSIDERFINANCE.COM 🔥
1. #PGR 539.4x
2. #CSCO 169.2x
3. #BMY 89.7x
4. #AXP 35.5x
5. #RR 21.7x

#OptionFlow #OptionsTrading #Trading

📈 Heavy institution #Equity #optionsvolume! PM Top Equity Activity from 🔥 INSIDERFINANCE.COM 🔥 1

📈 Heavy institution #Equity #optionsvolume!

PM Top Equity Activity from 🔥 INSIDERFINANCE.COM 🔥
1. #NVDA 276.7K
2. #BMY 142.3K
3. #PGR 99.4K
4. #NFLX 81.4K
5. #TSLA 65.9K

#OptionFlow #OptionsTrading #Trading

🎯 Momentum #Options Activity trade ideas! Heavy institutional #optionsvolume far above daily averag

🎯 Momentum #Options Activity trade ideas! Heavy institutional #optionsvolume far above daily average with strong consensus on direction.

PM Algo #TradeIdea from 🔥 INSIDERFINANCE.COM 🔥
#PGR, #CSCO, #BMY, #AXP, #RR

#OptionFlow #OptionsTrading #Trading

Breaking News: ( NYSE: #BMY ) 3 Drug Stocks to Buy at a Discount

Bristol Myers Squibb Announces Agreement with U.S. Government to Improve Affordability and Access to Critical Medicines for Americans Bristol Myers Squibb today announced an agreement with the U.S. government to provide Eliquis ®, an oral anticoagulant relied upon by millions of Americans daily, for free to the Medicaid program and to donate more than seven tons of Eliquis active pharmaceutical ingredient to ensure American supply chain resilience. Make Eliquis available to Medicaid for...

#BMS #BMY Bristol Myers Squibb Announces Agreement with U.S. Government to Improve Affordability and Access to Critical Medicines for Americans

www.stocktitan.net/news/BMS/bristol-myers-s...

Bought more #W7L - Building slowly - #BMY - Trading ahead statement in October so looking at this one.

🚨 Institutions #optionsvolume surge detected! PM Top Momentum Activity from 🔥 INSIDERFINANCE.COM

🚨 Institutions #optionsvolume surge detected!

PM Top Momentum Activity from 🔥 INSIDERFINANCE.COM 🔥
1. #GOSS 17.4x
2. #PLD 16.2x
3. #APH 14.0x
4. #AEO 7.3x
5. #BMY 5.8x

#OptionFlow #OptionsTrading #Trading

#BMY Bristol Myers Squibb Advances Lymphoma Research with New Targeted Protein Degradation and Cell Therapy Data at ASH 2025

www.stocktitan.net/news/BMY/bristol-myers-s...

Bristol Myers Squibb’s Breyanzi Approved by the U.S. FDA as the First and Only CAR T Cell Therapy for Adults with Relapsed or Refractory Marginal Zone Lymphoma (MZL) Bristol Myers Squibb (NYSE: BMY) announced FDA approval of Breyanzi (lisocabtagene maraleucel) on December 5, 2025, as the first and only CAR T therapy for adults with relapsed or refractory marginal zone lymphoma (MZL) after ≥2 prior systemic therapies.Approval was based on TRANSCEND FL MZL cohort results: ORR 95.5% (n=66), CR 62.1%, median duration of response not reached, and 90.1% of responders in response at 24 months; safety was consistent with prior data.

#BMY Bristol Myers Squibb’s Breyanzi Approved by the U.S. FDA as the First and Only CAR T Cell Therapy for Adults with Relapsed or Refractory Marginal Zone Lymphoma (MZL)

www.stocktitan.net/news/BMY/bristol-myers-s...

🚨 Institutions #optionsvolume surge detected! AM Top Momentum Activity from 🔥 INSIDERFINANCE.COM

🚨 Institutions #optionsvolume surge detected!

AM Top Momentum Activity from 🔥 INSIDERFINANCE.COM 🔥
1. #TSEM 4.2x
2. #ETOR 4.2x
3. #BMY 3.0x
4. #NFLX 2.5x
5. #EOSE 2.3x

#OptionFlow #OptionsTrading #Trading

Bristol Myers Squibb Announces Continuation of ADEPT-2 Phase 3 Study in Psychosis Associated with Alzheimer's Disease Bristol Myers Squibb (NYSE: BMS) announced on December 3, 2025 that the ADEPT-2 Phase 3 study in psychosis associated with Alzheimer’s disease will continue with additional patient enrollment after a blinded review identified site-level irregularities.The company excluded data from the affected sites before database lock, ran an independent interim efficacy and safety analysis with FDA consultation, and the Data Monitoring Committee recommended resuming enrollment to the original target population. BMS remains blinded to study data and expects ADEPT program readouts, including ADEPT-2, by end of 2026.

#BMS #BMY Bristol Myers Squibb Announces Continuation of ADEPT-2 Phase 3 Study in Psychosis Associated with Alzheimer's Disease

www.stocktitan.net/news/BMS/bristol-myers-s...

#BMY 🆙+3%✅ £5.11✅
Google & Bloomsbury Strategic Collaboration.
President of $GOOG in Europe, Middle East & Africa, said: "This collaboration demonstrates how Google Cloud's advanced AI capabilities,..can empower leading organizations to transform..."

RNS📸via Jim Wall on X

#BMY announce strategic collaboration with Google Cloud leveraging AI tools.

Bristol Myers Squibb Data at ASH 2025 Showcase Potential of Hematology Pipeline and Build Momentum for Next Generation Portfolio Bristol Myers Squibb (NYSE: BMY) disclosed more than 95 data disclosures, including 27 oral presentations, at ASH 2025 highlighting advances across multiple myeloma, lymphomas and myeloid diseases.Key clinical updates include durable responses with CELMoD agents: iberdomide (maintenance and combos) showing sustained MRD negativity in newly diagnosed multiple myeloma, golcadomide with continued efficacy at 24 months in aggressive B-cell lymphoma and extended follow-up in R/R FL and DLBCL, and a first-in-class BCL6 ligand-directed degrader showing encouraging activity in R/R NHL.Long-term liso-cel (Breyanzi) data show sustained benefit at 3–4 years in FL and LBCL; full safety profiles, including CRS and neurologic event rates, were reported.

#BMY Bristol Myers Squibb Data at ASH 2025 Showcase Potential of Hematology Pipeline and Build Momentum for Next Generation Portfolio

www.stocktitan.net/news/BMY/bristol-myers-s...